$OSP.ASX looks like sell off died already . #OSP #ASX
About the company
Osprey Medical Inc. (OSP) is a medical device company with operations based in USA. The Company is focused on protecting patients from the harmful effects of X-ray dye (contrast) used during commonly performed angiographic imaging procedures.
Fair Value Estimate 0.052c if it holds this level
About the company
Osprey Medical Inc. (OSP) is a medical device company with operations based in USA. The Company is focused on protecting patients from the harmful effects of X-ray dye (contrast) used during commonly performed angiographic imaging procedures.
Fair Value Estimate 0.052c if it holds this level
Transaction en cours:
Minnesota, United States and Melbourne, Australia – 29 October 2020 - Osprey Medical Inc. (ASX:OSP) (Osprey or the Company) today released its Appendix 4C – Quarterly Cash Flow Report for the period ending 30 September 2020.
Key Highlights
• Strong month on month growth in unit sales over the quarter despite COVID interruptions, on track to return to preCOVID levels
• Expanding sales under milestone distribution agreements signed with GE Healthcare to exclusively distribute Osprey
product across the EMEA region and Regional Health Care Group to exclusively distribute across Australia & New
Zealand
• Received European CE Marking approval for the 2nd generation DyeVert Power XT system
• Business remains well capitalised with a cash balance of US$7.0m / A$9.8 m1 as of 30 September 2020, with a further A$1.7 m funds raised via options exercised in October 2020
Key Highlights
• Strong month on month growth in unit sales over the quarter despite COVID interruptions, on track to return to preCOVID levels
• Expanding sales under milestone distribution agreements signed with GE Healthcare to exclusively distribute Osprey
product across the EMEA region and Regional Health Care Group to exclusively distribute across Australia & New
Zealand
• Received European CE Marking approval for the 2nd generation DyeVert Power XT system
• Business remains well capitalised with a cash balance of US$7.0m / A$9.8 m1 as of 30 September 2020, with a further A$1.7 m funds raised via options exercised in October 2020
Commentaire:
Waiting for high volume & good announcement
Transaction en cours:
Needs to break 2.5c to turn bullish again
Transaction en cours:
we should get the follow through